Assay of GCDFP-15 by ELISA: an available method for in vitro studies of functional differentiation in human breast cancer.
An enzyme-linked immunosorbent assay (ELISA) was applied to a light protein, isolated from human breast cyst fluid (BCF) termed "gross cystic disease fluid protein - 15 Kda" (GCDFP-15), a potential differentiation marker in in vitro human breast cancer studies. The detection limits of this procedure, performed in microtiter plates, were 0.5 to 250 ng/well corresponding to 10 ng/ml to 5 micrograms/ml of sample or antigen solution. Possible cross-reaction with various antigens, especially those found in culture media, were investigated. The correlation coefficient between enzymoassay and radioimmunoassay was 0.978. The results showed that quantification of GCDFP-15 by ELISA is a specific and highly sensitive method. This procedure may be of interest in in vitro studies on the functional differentiation of breast cancer cells.
Revillion-Carette
F
F
Laboratoire d'Endocrinologie Expérimentale, Centre Oscar Lambret, Lille, France.
Hornez
L
L
Vandewalle
B
B
Lefebvre
J
J
D001053:Apolipoproteins; D053399:Apolipoproteins D; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000032:analysis*; D002352:Carrier Proteins; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006023:Glycoproteins; D006801:Humans; D026901:Membrane Transport Proteins; D009363:Neoplasm Proteins / Q000032:analysis* / Q000276:immunology; D011863:Radioimmunoassay; D014407:Tumor Cells, Cultured
C024328:APOD protein, human; D001053:Apolipoproteins; D053399:Apolipoproteins D; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D006023:Glycoproteins; D026901:Membrane Transport Proteins; D009363:Neoplasm Proteins; C488892:PIP protein, human